{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:33:42Z","timestamp":1785224022919,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-na\u00efve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were randomized to receive upadacitinib 15\u00a0mg or 30\u00a0mg or MTX. Patients who did not achieve CDAI remission and had\u2009&lt;\u200920% improvement in tender and swollen joint counts at week 26 received rescue therapy (addition of MTX in the upadacitinib group and addition of upadacitinib in the MTX group). Efficacy assessments were evaluated over 5 years and are reported as observed (AO) for patients who received continuous monotherapy with upadacitinib 15\/30\u00a0mg or MTX and by randomized group applying non-responder imputation (NRI). Treatment-emergent adverse events (TEAEs) per 100 patient-years were summarized over 5 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 945 patients randomized and treated, 775 (82%) completed week 48 and entered the LTE on study drug. Higher proportions of patients consistently achieved disease activity targets over 5 years with upadacitinib than MTX. In AO analyses, 53%\/59% of patients attained CDAI remission with upadacitinib 15\/30\u00a0mg versus 43% with MTX at week 260. NRI analyses showed better CDAI, DAS28(CRP), and ACR responses with upadacitinib relative to MTX at week 260 (all comparisons, nominal <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). Upadacitinib treatment also resulted in numerically greater inhibition of structural joint progression through week 260 compared to MTX. Most TEAEs, serious AEs, and AEs leading to discontinuation were numerically higher in patients receiving upadacitinib 30\u00a0mg. Rates of serious infections, herpes zoster, creatine phosphokinase elevation, nonmelanoma skin cancer, and neutropenia were numerically higher with upadacitinib than MTX. The observed safety profile of upadacitinib over 5 years was consistent with earlier trial results and integrated phase 3 safety analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Upadacitinib showed better clinical responses versus MTX in patients with RA throughout the 5-year trial. Higher rates of several AEs were observed with upadacitinib, especially in the 30\u00a0mg group, compared to MTX. When used as monotherapy in MTX-na\u00efve patients, the approved upadacitinib 15\u00a0mg dose showed better long-term efficacy versus MTX and an overall favorable benefit-risk profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02706873.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03358-x","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:03:44Z","timestamp":1722247424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Ronald","family":"van Vollenhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilmo","family":"Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Mannucci","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Swierkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Aelion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"3358_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1.","journal-title":"Nat Rev Dis Primers"},{"key":"3358_CR2","unstructured":"Pincus T, Gibson KA, Castrejon I. Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013) 2013;71 Suppl 1:S9-19."},{"key":"3358_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3358_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3358_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10067-016-3243-8","volume":"35","author":"N Fatimah","year":"2016","unstructured":"Fatimah N, Salim B, Nasim A, et al. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol. 2016;35(5):1341\u20135. https:\/\/doi.org\/10.1007\/s10067-016-3243-8.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"3358_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/1744666X.2018.1465409","volume":"14","author":"S Ling","year":"2018","unstructured":"Ling S, Bluett J, Barton A. Prediction of response to methotrexate in rheumatoid arthritis. Expert Rev Clin Immunol. 2018;14(5):419\u201329. https:\/\/doi.org\/10.1080\/1744666X.2018.1465409.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9636","key":"3358_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(08)61000-4.","journal-title":"Lancet"},{"issue":"5","key":"3358_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779\u201387. https:\/\/doi.org\/10.1080\/14397595.2020.1782049.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"3358_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/BOR.0000000000000972","volume":"35","author":"S Cohen","year":"2023","unstructured":"Cohen S, Reddy V. Janus kinase inhibitors: efficacy and safety. Curr Opin Rheumatol. 2023;35(6):429\u201334. https:\/\/doi.org\/10.1097\/BOR.0000000000000972.","journal-title":"Curr Opin Rheumatol"},{"issue":"10139","key":"3358_CR10","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4.","journal-title":"Lancet"},{"issue":"10139","key":"3358_CR11","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"Lancet"},{"issue":"10","key":"3358_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of Upadacitinib Monotherapy in Methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a Multicenter, Multi-country, Randomized, Double-Blind, active Comparator-Controlled Trial. Arthritis Rheumatol. 2020;72(10):1607\u201320. https:\/\/doi.org\/10.1002\/art.41384.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3358_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to Methotrexate: results of a phase III, Double-Blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788\u2013800. https:\/\/doi.org\/10.1002\/art.41032.","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"3358_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2008250.","journal-title":"N Engl J Med"},{"issue":"10188","key":"3358_CR15","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2.","journal-title":"Lancet"},{"issue":"5 Suppl 39","key":"3358_CR16","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3358_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3358_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European League against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3358_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0950-3579(05)80189-x","volume":"9","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol. 1995;9(2):253\u201366. https:\/\/doi.org\/10.1016\/s0950-3579(05)80189-x.","journal-title":"Baillieres Clin Rheumatol"},{"issue":"Suppl 6","key":"3358_CR20","doi-asserted-by":"publisher","first-page":"vi16","DOI":"10.1093\/rheumatology\/kes281","volume":"51","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Massarotti EM. The new ACR\/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/kes281.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3358_CR21","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789\u201393.","journal-title":"J Rheumatol"},{"issue":"3","key":"3358_CR22","first-page":"743","volume":"26","author":"D van der Heijde","year":"1999","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van Der Heijde method. J Rheumatol. 1999;26(3):743\u20135.","journal-title":"J Rheumatol"},{"issue":"1","key":"3358_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.1780350105","volume":"35","author":"DM van der Heijde","year":"1992","unstructured":"van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35(1):26\u201334. https:\/\/doi.org\/10.1002\/art.1780350105.","journal-title":"Arthritis Rheum"},{"key":"3358_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3358_CR25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210457.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3358_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7\u201318. https:\/\/doi.org\/10.3899\/jrheum.171361.","journal-title":"J Rheumatol"},{"key":"3358_CR27","doi-asserted-by":"publisher","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1). https:\/\/doi.org\/10.1136\/rmdopen-2022-002735.","DOI":"10.1136\/rmdopen-2022-002735"},{"issue":"1","key":"3358_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12955-017-0813-7","volume":"15","author":"ED Bacci","year":"2017","unstructured":"Bacci ED, DeLozier AM, Lin CY, et al. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health Qual Life Outcomes. 2017;15(1):239. https:\/\/doi.org\/10.1186\/s12955-017-0813-7.","journal-title":"Health Qual Life Outcomes"},{"key":"3358_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/annrheumdis-2021-eular.530","volume":"80","author":"R van Vollenhoven","year":"2021","unstructured":"van Vollenhoven R, Takeuchi T, Aelion J, et al. POS0655 long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis: 3-year results from SELECT-EARLY study [Abstract]. Ann Rheum Dis. 2021;80:568\u201369.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3358_CR30","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","volume":"75","author":"J Askling","year":"2016","unstructured":"Askling J, Berglind N, Franzen S, et al. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis. 2016;75(10):1789\u201396. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208105.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3358_CR31","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.38385","volume":"66","author":"RL Gross","year":"2014","unstructured":"Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472\u201381. https:\/\/doi.org\/10.1002\/art.38385.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"3358_CR32","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886\u201395. https:\/\/doi.org\/10.1002\/art.22864.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T10:08:17Z","timestamp":1722247697000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3358"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03358-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies were conducted per the International Conference on Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Study-related documents were approved by independent ethics committees and institutional review boards. All patients provided written, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie Inc. was the trial sponsor, and the trial was designed by AbbVie Inc., the authors, and investigators. Clinical data were collected by the investigators, their teams, and AbbVie Inc. AbbVie Inc. was involved in data analysis, the interpretation of results and the preparation, review and approval of the final version of this report. All the authors had access to the data, reviewed and approved the final version, made the decision to submit the manuscript for publication, and attest to the accuracy and completeness of the data. The corresponding author had access to all relevant data and the final responsibility to submit for publication. A medical writer, employed by AbbVie Inc., assisted with preparing an initial draft under the direction of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of authors and Sponsor"}},{"value":"Some of the results reported in this manuscript were originally presented at the American College of Rheumatology 2023 Congress, as follows: van Vollenhoven R et al., Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial. <i>Arthritis Rheumatol<\/i>. 2023; 75 (suppl 9); .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"R van Vollenhoven: Research Support (institutional grants): BMS, UCB; support for educational programs (institutional grants): AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, UCB; consultancy, for which institutional and\/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Pfizer, RemeGen, UCB; speaker, for which institutional and\/or personal honoraria were received: AbbVie, AstraZeneca, BMS, Galapagos, GSK, Janssen, Pfizer, UCB.V Strand: Consultant for AbbVie, Alpine Immune Sciences, Alumis, Amgen, AstraZeneca, Bayer, Blackrock, BMS, Boehringer Ingelheim, Celltrion, Ermium, Genentech\/Roche, GlaxoSmithKline, Horizon, Inmedix, Janssen, Kiniksa, Lilly, Merck, MiMedx, Novartis, Omeros, Pfizer, R-Pharm, Regeneron, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix, and Urica.T Takeuchi: Grant\/research support from AbbVie and Eisai; consulting fees from AbbVie, Astellas Pharma, Eli Lilly Japan, and Gilead Sciences; speaker\/honoraria from AbbVie, Astellas Pharma, Eisai, Eli Lilly Japan, Gilead Sciences, and Pfizer Japan.J Aelion: Grant or research support: AbbVie, Acceleron, Acelyrin, Aclaris Therapeutics, Alpine Immune Sciences, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly, Galapagos, GSK, Horizon, Janssen, Novartis, Selecta, UCB, Ventyx; consultancy for AbbVie, Amgen, BMS, Janssen, Novartis; speaker for AbbVie and Amgen. N Ch\u00e1vez: Speakers bureau for AbbVie, Janssen, and Pfizer; consultant of AbbVie, Janssen, and Pfizer; grant\/research support from AbbVie, Galapagos, Gilead, Pfizer, and Sanofi. P Mannucci Walter: consulting fees from AbbVie; grant\/research support from AbbVie, Bristol-Myers Squibb, Lilly, Genentech\/Roche, GSK, Janssen, and UCB. Atul Singhal: No conflicts of interest to declare. J Swierkot: Speaker, research grants, and consulting fees from AbbVie, Amgen, Astra Zeneca, Celltrion, Eli Lilly, Novartis, Sandoz, Pfizer, Roche, BMS, UCB, MSD, Accord, and Janssen.N Khan, X Bu, Y Li, SK Penn, HS Camp: Employee of AbbVie and may hold stock or options.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}